The global Phase III trials of OLN324 in DME and wAMD will be launched in the second half of 2026.

Lingdolinurad lowers the incidence of acute gout flares in phase 2b studies—an advantage that remains challenging for existing gout therapies.

MSD acquired tulisokibart in 2023 through its buyout of Prometheus Therapeutics.

BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative ...

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies< Extends NeOnc’s ...

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for ...

The FDA’s efforts are meant to reduce phase 1 timelines by six to 12 months, Diamantas said. They include what he called an ...

The Indian Council for Medical Research has established the ICMR-Network for Phase 1 Clinical Trials. Here we describe identification of the need to establish the Network and further elaborate on its ...

Announcing a new article publication for BIO Integration journal. Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines ...

DURIPANC is a follow-up to the AIM/Erasmus Medical Center Named Patient Program utilizing Ampligen as a monotherapy in late-stage pancreatic cancer, where data suggested impressive improvements in ...

HHS Secretary Robert F. Kennedy Jr. wants to speed up clinical trials in the United States.“A recent study found that China ...

Clearance enables Phase 2 evaluation of NEO212, the Company’s oral perillyl alcohol-temozolomide conjugate, in the United ...